医薬品連続生産の世界市場2020-2072

◆英語タイトル:GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FORECAST 2020-2028
◆商品コード:INK20MY061
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:168
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは医薬品連続生産の世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、製品別(統合連続システム、半連続システム、制御・ソフトウェア)分析、用途別(最終製品製造、API製造)分析、エンドユーザー別(製薬会社、受託製造組織、その他)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・医薬品連続生産世界市場:製品別(統合連続システム、半連続システム、制御・ソフトウェア)
・医薬品連続生産世界市場:用途別(最終製品製造、API製造)
・医薬品連続生産世界市場:エンドユーザー別(製薬会社、受託製造組織、その他)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global pharmaceutical continuous marketing market is anticipated to register a CAGR of 8.45% over the forecast period of 2020-2028. The factors contributing to the growth of the market are the rising adoption of pharmaceutical continuous marketing systems, growth opportunities in unexplored emerging economies, and increasing government initiatives for the adoption of pharmaceutical continuous marketing systems. Further, initiatives taken by the FDA for promoting the use of pharmaceutical CM systems and their advantage over the existing drug manufacturing process are the other crucial factors fueling the market growth.

MARKET INSIGHTS
Continuous manufacturing is a developed manufacturing process to prepare pharmaceutical products in a short span of time with improved quality, enhanced yield, and lower cost of production. The opportunities offered by the emerging untapped markets are an enhanced pharmaceutical infrastructure, a growing number of pharmaceutical industries, and a surge in demand for pharmaceutical CM systems. The market is categorized into an integrated continuous system, semi-continuous system, and control & software depending on the product. The integrated continuous system dominates the global market in terms of revenue and market share. It is attributed to low cost, time efficiency, high quality of the product productivity, and no manual. However, the higher cost of pharmaceutical manufacturing systems continuous systems hinders the market growth. The intensity of competition in the market is moderate to high, owing to the high growth of the market but low product differentiation.

REGIONAL INSIGHTS
The global pharmaceutical continuous marketing market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America dominated the market in terms of revenue, and is projected to maintain the trend until the end of the forecast period. This is attributed to major factors such as the presence of well-developed infrastructure in pharmaceutical industries, together with a rise in the use of continuous manufacturing systems, among various other factors.

COMPETITIVE INSIGHTS
There are many prominent players functioning and registering their presence in the global market, such as Eli Lilly and Company, Hosokawa Micron Corporation, GEA Group, L.B. Bohle Glatt GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. DEVELOPMENT OPPORTUNITIES IN UNTAPPED EMERGING MARKETS
3.2.2. INCREASED ADOPTION OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
3.2.3. RISING GOVERNMENT INITIATIVES FOR THE ADOPTION OF CONTINUOUS MANUFACTURING SYSTEMS
3.3. KEY RESTRAINTS
3.3.1. INCREASING CUSTOMER ANTICIPATIONS
3.3.2. LACK OF DEMAND FOR THE CONTINUOUS MANUFACTURING SYSTEMS IN UNDERDEVELOPED COUNTRIES
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCE ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. REGULATORY FRAMEWORK
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY PRODUCT
5.1. INTEGRATED CONTINUOUS SYSTEM
5.2. SEMI-CONTINUOUS SYSTEM
5.3. CONTROL & SOFTWARE
6. MARKET BY APPLICATION
6.1. FINAL DRUG PRODUCT MANUFACTURING
6.2. API MANUFACTURING
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT MANUFACTURING ORGANIZATIONS
7.3. OTHER END-USERS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. THE UNITED STATES
8.1.2. CANADA
8.2. EUROPE
8.2.1. THE UNITED KINGDOM
8.2.2. FRANCE
8.2.3. GERMANY
8.2.4. ITALY
8.2.5. RUSSIA
8.2.6. BELGIUM
8.2.7. POLAND
8.2.8. REST OF EUROPE
8.3. ASIA PACIFIC
8.3.1. CHINA
8.3.2. JAPAN
8.3.3. INDIA
8.3.4. AUSTRALIA & NEW ZEALAND
8.3.5. SOUTH KOREA
8.3.6. THAILAND
8.3.7. INDONESIA
8.3.8. VIETNAM
8.3.9. REST OF ASIA PACIFIC
8.4. REST OF WORLD
8.4.1. LATIN AMERICA
8.4.2. MIDDLE EAST & AFRICA
9. COMPANY PROFILES
9.1. COPERION GMBH
9.2. ELI LILLY & COMPANY
9.3. GEA GROUP AG
9.4. GEBRUDER LODIGE MASCHINENBAU GMBH
9.5. GLATT GMBH
9.6. HOSOKAWA MICRON CORPORATION
9.7. KORSCH AG
9.8. L.B. BOHLE MASCHINEN + VERFAHREN GMBH
9.9. MUNSON MACHINERY COMPANY
9.10. PFIZER INC
9.11. SIEMENS HEALTHINEERS
9.12. SYNTEGON (FORMERLY BOSCH PACKAGING TECHNOLOGY)
9.13. THERMO FISHER SCIENTIFIC INC



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[医薬品連続生産の世界市場2020-2072]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆